Developments in the management of idiopathic pulmonary fibrosis
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Question 1
Answer: c. IPF has an incidence in the UK of around 5,000 new cases per year and the prevalence is around 15-25 in 100,000.
Two randomised double-blind placebo-controlled studies have assessed the use of perfenidone in adults with mild-to-moderate IPF. When the 2,403mg-dose arms of both studies were combined what was the difference in mean decline in percentage of predicted forced vital capacity (FVC) with pirfenidone compared with placebo?
e. 10%
Question 3
Answer: b. A significantly reduced mean decline in percentage of predicted FVC was seen with pirfenidone 2,403mg daily compared with placebo in one study (-8.0% vs. -12.4%, p=0.001), but not in the other (-9.0% vs. -9.6%, p=0.501). When the 2,403mg-dose arms of both studies were combined there was a significant treatment effect in favour of pirfenidone (-8.5% vs. -11.0%, p=0.005).
What is the approximate 5-year survival rate for patients with IPF?
e. 65%
Question 2
Answer: b. With a median survival of 3 years and 5-year survival rate of around 20%, IPF has a prognosis worse than many cancers.
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Answer: e. Elevated liver enzyme levels have been reported with perfenidone and liver function tests should be carried out before and during treatment. Hepatic transaminase and bilirubin levels should be assessed before and periodically during treatment with nintedanib.
Which one of the following should be performed before and during treatment with pirfenidone or nintedanib? 
Question 4
Answer: a. Treatment with nintedanib 150mg twice daily produced a statistically significant reduction in annual rate of decline of FVC in both studies (annual difference compared with placebo 125mL, p<0.001 and 94mL, p<0.001).
